High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Butrym, Aleksandra ^a   Majewski, Miroslaw ^b   Dzietczenia, Justyna ^a   Kuliczkowski, Kazimierz ^a   Mazur, Grzegorz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Nicolaus Copernicus Hospital   (Poland)

Author keywords

CD74; Chronic lymphocytic leukemia; Expression; ZAP70

Indexed keywords

CD74 ANTIGEN; PROTEIN KINASE ZAP 70; B LYMPHOCYTE ANTIGEN; C REACTIVE PROTEIN; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN E RECEPTOR; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALYSIS OF VARIANCE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; INVARIANT CHAIN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECEPTORS, IGE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84875829845     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0560-5     Document Type: Article

References (36)

1. Rai KR, Wasil T. History of chronic lymphocytic leukemia. Chronic lymphoid leukemias second edition. New York: National Cancer Institiute; 2001. p. 1-7.
2. Gribben JG. How I treat CLL up front. Blood. 2010;115:187-97.
3. Bazargan A, Tam CS, Keating MJ. Predicting survival of chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12:393-403.
4. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev. 2010;10:37-50.
5. Houlston RS, Sellick G, Yuille M, Matutes E, Catovsky D. Causation of chronic lymphocytic leukemia-insights from familial disease. Leuk Res. 2003;27:871-6.
6. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13:5556s-63s.
7. Matza D, Wolstein O, Dikstein R, Schachar I. Invariant chain induces B cell maturation by activating a TAFII105-NF- κB-dependent transcription program. J Biol Chem. 2001;276:27203-6.
8. Shachar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma. 2011;52:1446-54.
9. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197:1467-76.
10. Li GQ, Xie J, Lei XY, Zhang L. Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3 K/Akt pathway. World J Gastroenterol. 2009;15:5541-8.
11. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma cells and is promising target for therapy. Clin Cancer Res. 2004;10:6606-11.
12. Ishigami S, Natsugoe S, Tokuda K, et al. Invariant chain expression in gastric cancer. Cancer Lett. 2001;168:87-91.
13. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158:1639-51.
14. McClelland M, Zhao L, Carskadon S, Arenberg D. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol. 2009;174:638-46.
15. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2000;8:210-5.
16. Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79:2115-24.
17. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med. 2000;343:1910-6.
18. Seiffert M, Dietrich S, Jethwa A, Glimm H, Lichter P, Zenz T. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1023-31.
19. Jäger U, Shehata M, Heintel D, et al. Genetics in chronic lymphocytic leukaemia: impact for prognosis and treatment decisions. Hematology education: the education program for the annual congress of the European Hematology Association. 2007;1:115-121.
20. Ghia P, Stomatopoulos K, Belessi C, et al. European Research Initiative on CLL: ERIC recommendations in IGVH gene mutational status analysis in chronic lymphocytic leukemia [editorial]. Leukemia. 2007;21:1-3.
21. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell. 2005;16:5061-9.
22. Binsky I, Lantner F, Grabovsky V, et al. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol. 2010;184:4761-9.
23. Starlets D, Gore Y, Binsky I, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107:4807-16.
24. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA. 2007;104:13408-13.
25. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104:3705-11.
26. Frölich D, Blaßfeld D, Reiter K, et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther. 2012;14:R54.
27. Lantner F, Starlets D, Gore Y, et al. CD74 induces TAp63 expression leading to B-cell survival. Blood. 2007;110:4303-11.
28. Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008;283:2784-92.
29. Souwer Y, Chamuleau ME, van de Loosdrecht AA, et al. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival. Br J Haematol. 2009;145:334-43.
30. Gordin M, Tesio M, Cohen S, et al. C-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol. 2010;185:2020-31.
31. Maharshak N, Cohen S, Lantner F, et al. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol. 2010;16:3258-66.
32. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112:1923-30.
33. Beswick EJ, Reyes VR. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol. 2009;15:2855-61.
34. Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin Immunol. 2002;14:19-26.
35. Fruman DA. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004;16:314-20.
36. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7:122-33.